ArticleInfection and immunity2007
Agonists of Toll-like receptors 3, 4, 7, and 9 are candidates for use as adjuvants in an outer membrane vaccine against Neisseria meningitidis serogroup B.
Article in Infection and immunity, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 63 citations in OpenAlex.
- Enhancing Control ofAnimals : an open access journal from MDPI · 2024Article
- Th1-polarized MtrE-based gonococcal vaccines display prophylactic and therapeutic efficacy.Emerging microbes & infections · 2023Article
- Role of Bacterial Extracellular Vesicles in Manipulating Infection.Infection and immunity · 2023Review
- "Just right" combinations of adjuvants with nanoscale carriers activate aged dendritic cells without overt inflammation.Immunity & ageing : I & A · 2023Article
- Bacteria derived extracellular vesicles in the pathogenesis and treatment of gastrointestinal tumours.Frontiers in oncology · 2022Review
- An OMV-Based Nanovaccine Confers Safety and Protection against PathogenicNanomaterials (Basel, Switzerland) · 2020Article
- OMV Vaccines and the Role of TLR Agonists in Immune Response.International journal of molecular sciences · 2020Review
- Exploiting bacterial outer membrane vesicles as a cross-protective vaccine candidate against avian pathogenic Escherichia coli (APEC).Microbial cell factories · 2020Article
- Optimization of an Experimental Vaccine To Prevent Escherichia coli Urinary Tract Infection.mBio · 2020Article
- Pre-treatment with the viral Toll-like receptor 3 agonist poly(I:C) modulates innate immunity and protects neutropenic mice infected intracerebrally with Escherichia coli.Journal of neuroinflammation · 2020Article
- Article
- Delineating the Plausible Molecular Vaccine Candidates and Drug Targets of Multidrug-ResistantFrontiers in cellular and infection microbiology · 2019Article
- Bacterial Outer Membrane Vesicles Provide Broad-Spectrum Protection against Influenza Virus Infection via Recruitment and Activation of Macrophages.Journal of innate immunity · 2019Article
- TLR agonist combinations that stimulate Th type I polarizing responses from human neonates.Innate immunity · 2018Article
- Article
- Vaccination with Klebsiella pneumoniae-derived extracellular vesicles protects against bacteria-induced lethality via both humoral and cellular immunity.Experimental & molecular medicine · 2015Article
- Article
- B cell TLRs and induction of immunoglobulin class-switch DNA recombination.Frontiers in bioscience (Landmark edition) · 2012Review
- Selective TRIF-dependent signaling by a synthetic toll-like receptor 4 agonist.Science signaling · 2012Article
- Laser vaccine adjuvant for cutaneous immunization.Expert review of vaccines · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The bacterium Neisseria meningitidis is the causative agent of meningitis and sepsis. A generally effective vaccine against N. meningitidis serogroup B is not yet available, but outer membrane vesicle vaccines are in development. These vaccines contain lipopolysaccharide (LPS). The inclusion of N. meningitidis wild-type LPS in a vaccine is controversial because of its high toxicity. Therefore, the adjuvant activity of a panel of different Toll-like receptor (TLR) agonists in combination with LPS-deficient meningococcal outer membrane complexes was compared after immunization of mice. The results demonstrate that TLR3, TLR4, TLR7, and TLR9 agonists enhance immune responses against LPS-deficient outer membrane complexes. Their adjuvant activity was characterized by higher levels of antigen-specific immunoglobulin G (IgG), IgG2a, and IgG2b; a higher IgG2a/IgG1 ratio; lower total IgE levels; and most importantly, higher serum bactericidal antibody titers compared to LPS-deficient outer membrane complexes alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.